3 results about "Tumor suppressor proteins" patented technology

A method of obtaining cell derived vesicles comprising an active wild-type p53 is disclosed. The method comprising: (i) isolating cell derived vesicles from a biological sample comprising cells; and (ii) treating the cell derived vesicles with a DNA damaging agent, or the method comprising: (i) treating cells with a DNA damaging agent; and (ii) isolating cell derived vesicles from a biological sample comprising the cells. A proteinaceous preparation comprising cell derived vesicles and a pharmaceutical composition comprising the proteinaceous preparation are also disclosed. Methods of treating a disease, disorder or condition associated with a mutant or a nonfunctional p53 protein and methods of inducing apoptosis of a target cell comprising a mutant or a nonfunctional p53 protein are also disclosed.

This invention is based on in vitro transcription RNA compounds or in vitro synthetic RNA compounds for the translation of tumor suppressor proteins in subjects suffering from proliferative diseases such as cancer. The invention provides RNA compounds and compositions for their delivery or administration to subjects.

The application belongs to the technical field of biological medicine, and particularly relates to a tumor acidity response functional polypeptide capable of targeting and activating p53 and application thereof. The amino acid sequence of the polypeptide is shown as SEQ ID NO. 1. The application first designs and expresses the tumor acidity response functional polypeptide Trx-AAN-pHLIP-NLS-PMI (TApNP) capable of targeting and activating the tumor suppressor protein p53, and comprehensively evaluates the physical and chemical characteristics, intracellular internalization, nuclear uptake and anti-tumor activity of the polypeptide. The results show that in a weak acid environment, the TApNP can deliver PMI into cells and guide it to the cell nucleus, and effectively inhibit the proliferation of tumor cells.